Published in Blood on July 02, 2008
Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease | NCT00462189
Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia | NCT00021983
Immunotoxin in Treating Patients With Leukemia or Lymphoma | NCT00002765
How I treat hairy cell leukemia. Blood (2009) 1.62
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res (2011) 1.25
Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood (2011) 1.11
Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia. Clin Cancer Res (2013) 0.81
Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res (2013) 0.81
Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer (2015) 0.79
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med (2001) 2.65
The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med (1990) 2.34
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res (2002) 2.30
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol (2005) 2.16
Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax (2007) 1.91
The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr Opin Immunol (2005) 1.63
Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res (2000) 1.33
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood (2002) 1.32
HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res (2005) 1.32
Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood (1993) 1.29
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer (2004) 1.27
A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood (1993) 1.27
A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. Clin Cancer Res (2005) 1.26
B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia. Cytometry B Clin Cytom (2003) 1.26
Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res (1991) 1.26
A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest (2006) 1.20
Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers (2008) 1.20
CD22, a B cell-specific receptor, mediates adhesion and signal transduction. J Immunol (1993) 1.12
CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. Semin Immunol (1998) 1.10
Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol (2003) 1.09
Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene (2007) 1.06
Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood (2001) 1.04
Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease. Br J Haematol (2003) 1.03
The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies. Cell Immunol (1989) 0.97
Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma. Eur J Haematol (2006) 0.97
Beta 2-microglobulin: its significance and clinical usefulness. Ann Clin Lab Sci (1990) 0.96
Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood (1995) 0.96
The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma. Haematologica (2002) 0.92
Levels of soluble CD137 are enhanced in sera of leukemia and lymphoma patients and are strongly associated with chronic lymphocytic leukemia. Leukemia (2005) 0.89
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia (2006) 0.89
Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer (2006) 0.89
Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction. Clin Cancer Res (2006) 0.89
Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity. Cancer Res (1993) 0.88
Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. Eur J Haematol (2006) 0.87
Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Ann Oncol (2002) 0.85
Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia. Mediators Inflamm (2006) 0.85
Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice. Cancer Res (1993) 0.83
Identification of the soluble granulocyte-macrophage colony stimulating factor receptor protein in vivo. Blood (2000) 0.83
Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma. Tumour Biol (2003) 0.82
Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia. Cancer J Sci Am (2000) 0.82
Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL. Klin Padiatr (2006) 0.80
Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies. Leuk Lymphoma (2004) 0.79
Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients. Leukemia (2002) 0.79
Circulating soluble-CD30 (sCD30) in patients with HCV-related chronic hepatitis and in patients with alcoholic liver disease. Hepatogastroenterology (2002) 0.79
The significance of soluble CD138 in diagnosis of monoclonal gammopathies. Neoplasma (2006) 0.79
Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera. Clin Chem Lab Med (2006) 0.78
Circulating levels and clinical significance of soluble CD86 in myeloma patients. Br J Haematol (2006) 0.78
Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression. Cancer (2001) 0.77
Soluble histocompatibility antigen class I in breast cancer patients in relation to tumor burden. Cancer (1991) 0.76
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood (2010) 5.95
Immunotoxin therapy of cancer. Nat Rev Cancer (2006) 3.93
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res (2007) 3.30
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol (2009) 3.13
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother (2006) 2.86
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer (2006) 2.70
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood (2012) 2.52
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med (2013) 2.39
Immunotoxin treatment of cancer. Annu Rev Med (2007) 2.36
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res (2002) 2.30
Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood (2011) 2.28
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol (2005) 2.16
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol (2012) 2.15
Mesothelin expression in human lung cancer. Clin Cancer Res (2007) 2.10
SWAP-70 is a guanine-nucleotide-exchange factor that mediates signalling of membrane ruffling. Nature (2002) 2.08
Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res (2005) 2.05
Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res (2006) 1.99
Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications. Haematologica (2011) 1.89
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol (2009) 1.86
Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol (2005) 1.84
Minimal residual disease: what are the minimum requirements? J Clin Oncol (2014) 1.76
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood (2008) 1.74
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A (2008) 1.66
Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res (2010) 1.64
Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med (2005) 1.63
VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood (2009) 1.59
Evidence of canonical somatic hypermutation in hairy cell leukemia. Blood (2011) 1.55
In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem (2004) 1.54
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res (2011) 1.54
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin Cancer Res (2009) 1.53
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol (2007) 1.52
Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res (2010) 1.44
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci U S A (2012) 1.42
Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol (2006) 1.42
PRAME expression in hairy cell leukemia. Leuk Res (2008) 1.41
New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res (2005) 1.39
Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level. Cancer Res (2008) 1.34
Immunotoxins for leukemia. Blood (2014) 1.33
HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res (2005) 1.32
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood (2010) 1.30
Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc Natl Acad Sci U S A (2006) 1.30
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci U S A (2011) 1.29
A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol Cancer Ther (2012) 1.27
Mesothelin is shed from tumor cells. Cancer Epidemiol Biomarkers Prev (2006) 1.24
Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry B Clin Cytom (2010) 1.21
A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. Cancer Res (2010) 1.21
Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res (2006) 1.19
Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol (2010) 1.19
Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. Blood (2003) 1.17
Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res (2002) 1.15
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium. Am J Hematol (2014) 1.15
Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol (2003) 1.13
CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. Clin Cancer Res (2009) 1.10
Evolution and expression of chimeric POTE-actin genes in the human genome. Proc Natl Acad Sci U S A (2006) 1.09
Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol (2003) 1.09
Flow cytometric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow. Cytometry B Clin Cytom (2005) 1.08
NGEP, a prostate-specific plasma membrane protein that promotes the association of LNCaP cells. Cancer Res (2007) 1.08
High expression of a cytokeratin-associated protein in many cancers. Proc Natl Acad Sci U S A (2006) 1.08
Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma (2013) 1.06
Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood (2013) 1.06
Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res (2006) 1.04
Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts. Clin Cancer Res (2011) 1.04
FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood (2007) 1.03
Flow cytometric immunophenotyping of cerebrospinal fluid. Curr Protoc Cytom (2008) 1.03
Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J Immunother (2006) 1.03
A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice. J Immunother (2010) 1.03
Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation. Br J Haematol (2007) 1.01
Effectiveness of anti-folate receptor beta antibody conjugated with truncated Pseudomonas exotoxin in the targeting of rheumatoid arthritis synovial macrophages. Arthritis Rheum (2005) 1.00
Characteristic CD103 and CD123 expression pattern defines hairy cell leukemia: usefulness of CD123 and CD103 in the diagnosis of mature B-cell lymphoproliferative disorders. Am J Clin Pathol (2011) 0.98
Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Mol Cancer Ther (2002) 0.98
Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res (2013) 0.97
Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies. Clin Cancer Res (2005) 0.97
Flow cytometry immunophenotyping of hematolymphoid neoplasia. Methods Mol Biol (2011) 0.96